Actinium Pharmaceuticals has begun patient enrollment in the RADIANZ imaging trial for ATNM-400, its first-in-class HER3-targeting radiotherapy. The study will

Actinium Pharmaceuticals has begun patient enrollment in the RADIANZ imaging trial for ATNM-400, its first-in-class HER3-targeting radiotherapy. The study will test its pan-cancer potential in solid tumors excluding prostate cancer, following preclinical data.